Table 2.
Clinicopathological characteristics of BC-BrM from the QBBM cohort stratified by B7-H3 expression.
| Characteristic | Negative (n (%)) |
Positive (n (%)) |
p Value | Statistical Test | |
|---|---|---|---|---|---|
| Primary breast (n = 61) | Subtype | ||||
| ER+ | 5 (28%) | 13 (72%) | 0.529 | Chi-square | |
| HER2+ | 3 (20%) | 12 (80%) | |||
| TNBC | 3 (11%) | 25 (89%) | |||
| Total | 11 (18%) | 50 (82%) | |||
| Tumour Grade | |||||
| 1/2 | 3 (20%) | 12 (80%) | 0.993 | Chi-square | |
| 3 | 8 (19%) | 35 (81%) | |||
| Total | 11 (19%) | 47 (81%) | |||
| Time to Neurosurgery (Median Years) |
2.910335 | 2.514716 | 0.597 | Welch’s t test | |
| 0.047 | F test | ||||
| Brain Metastasis (n = 80) | B7-H3 staining | 12 (15%) | 68 (85%) | 0.6518 | * Fisher’s exact test |
* Compared to total primary breast cancers.